Research Topics
Genomes and GenesSpecies | Christopher van DyckSummaryAffiliation: Yale University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer diseaseC H van Dyck
Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, Conn 06520, USA
Arch Neurol 55:1460-6. 1998..However, previous research has shown minimal effect of the epsilon4 allele on regional cerebral blood flow (rCBF) and metabolism in patients with probable AD...
Cognitive and psychiatric effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing home studyChristopher H van Dyck
Azheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
Int Psychogeriatr 21:138-47. 2009..The aim of this study is to determine whether B12 replacement would ameliorate cognitive and psychiatric symptoms in elderly subjects with dementia and low serum B12 levels...- A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezilChristopher H van Dyck
Department of Psychiatry, Yale University, New Haven, Connecticut 06510, USA
Am J Geriatr Psychiatry 14:428-37. 2006..The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses... - Understanding the latest advances in pharmacologic interventions for Alzheimer's diseaseChristopher H van Dyck
Alzheimer s Disease Research Unit, Yale University School of Medicine, 1 Church Street, New Haven, CT 06510, USA
CNS Spectr 9:24-8. 2004..The clinical efficacy and tolerability of memantine monotherapy and combination therapy in patients with AD will be presented. Finally, the role of nonpharmacologic intervention will be discussed... - Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotypeChristopher H van Dyck
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
Am J Psychiatry 161:525-31. 2004..In vitro studies of nonneural cells have suggested that the long allele may have higher transcriptional activity than the short allele. However, the relevance of these findings for SERT levels in the brain remains unclear... - A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer diseaseChristopher H van Dyck
Yale University School of Medicine, New Haven, CT 06510, USA
Alzheimer Dis Assoc Disord 21:136-43. 2007..The type and incidence of adverse events were similar in both groups... - Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 geneChristopher H van Dyck
Department of Psychiatry, Yale University School of Medicine, One Church Street, New Haven, CT 06510, USA
J Nucl Med 46:745-51. 2005..Previous investigations of the effects of the SLC6A3 polymorphism on DAT availability in smaller samples of humans have yielded divergent results... - Striatal dopamine transporters correlate with simple reaction time in elderly subjectsChristopher H van Dyck
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, United States
Neurobiol Aging 29:1237-46. 2008..These results demonstrate that a loss of nigrostriatal dopaminergic function likely contributes to slowing of reaction speed with advancing age... - Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorderChristopher H van Dyck
Department of Psychiatry, Yale University School of Medicine, Cognitive Disorders Clinic, New Haven, CT 06510, USA
Am J Psychiatry 159:309-12. 2002..The authors examined whether patients with attention deficit hyperactivity disorder (ADHD) have altered striatal dopamine transporter levels, which may explain psychostimulant effects in this disorder... - Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetriesChristopher H van Dyck
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
Am J Geriatr Psychiatry 10:36-43. 2002..These findings have implications not only for healthy aging but also for neurodegenerative disorders such as PD... - Neuroimaging in Alzheimer's disease: relevance for treatmentC H van Dyck
Alzheimer s Disease Research Unit, CB 2041, Yale University School of Medicine, 1 Church Street, Suite 600, New Haven, CT 06510, USA
Curr Psychiatry Rep 3:13-9. 2001..Neuroimaging studies of AD patients and asymptomatic subjects who carry the apolipoprotein E e4 allele suggest that these individuals may be particularly suitable for testing candidate prevention therapies for AD... - Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigmC H van Dyck
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Nucl Med Biol 27:715-22. 2000..These results demonstrate feasibility of equilibrium imaging with [(18)F]deuteroaltanserin and suggest that it may be superior to [(18)F]altanserin as a PET radioligand... - Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECTC H van Dyck
Department of Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
Neurobiol Aging 21:497-501. 2000..5% over the age range 18 to 88, or approximately 4.2% per decade. These results demonstrate reductions in the availability of central SERT binding sites with age in living human subjects... - Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study GroupC H van Dyck
Department of Psychiatry, Yale University School of Medicine, New Haven, Conn 06520, USA
Arch Gen Psychiatry 57:157-64. 2000..The efficacy of extended-release physostigmine salicylate, an acetylcholinesterase inhibitor, was evaluated in 850 subjects with mild-to-moderate Alzheimer disease (AD) in a multicenter trial... - Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysisTimothy Kleiman
Alzheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
Dement Geriatr Cogn Disord 22:73-82. 2006..This study aimed to determine whether ApoE epsilon4 dose is related to the progression of cognitive and functional decline in AD patients by combined retrospective and prospective analyses... 
123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairmentEffie M Mitsis
Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA
J Nucl Med 50:1455-63. 2009..However, the status of this receptor in mild or prodromal AD has remained the subject of controversy...- Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECTEffie M Mitsis
Yale University School of Medicine, New Haven, CT 06510, USA
Neurobiol Aging 30:1490-7. 2009..These results in living human subjects corroborate postmortem reports of decline in high affinity nicotine binding with age and may aid in elucidating the role of beta(2)-nAChRs in cognitive aging... - Regional distribution and behavioral correlates of 5-HT(2A) receptors in Alzheimer's disease with [(18)F]deuteroaltanserin and PETLekshmi Santhosh
Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, CT 06510, USA
Psychiatry Res 173:212-7. 2009..However, in a limited AD patient sample, they fail to demonstrate a relationship between regional 5-HT(2A) binding and major behavioral symptoms... - [123I]5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptor availability in the aging human brainEffie M Mitsis
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
Ann N Y Acad Sci 1097:168-70. 2007..Preliminary results have confirmed postmortem reports of age-related decline in high-affinity nicotine binding with age and may elucidate the role of beta(2)-nAChRs in the cognitive decline associated with aging... - 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phaseKelly P Cosgrove
Yale University School of Medicine, New Haven, Connecticut, USA
J Nucl Med 48:1633-40. 2007..We examined the availability of nAChR containing the beta(2) subunit in healthy men and women and the influence of menstrual phase among women... - Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycleSusan E Best
Department of Psychiatry, Yale University School of Medicine, Suite 600, One Church Street, New Haven, CT 06510, USA
Psychopharmacology (Berl) 183:181-9. 2005..Although the present investigation did not confirm previous reports of gender differences in striatal DAT availability, controlling for gender in such studies still seems advisable... - 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibilityJulie K Staley
Department of Psychiatry, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA
J Nucl Med 46:1466-72. 2005..The feasibility and reproducibility of the bolus-plus-constant-infusion paradigm for equilibrium modeling of (123)I-5-IA using SPECT in healthy nonsmokers was studied... - Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smokingJulie K Staley
Yale University School of Medicine, 950 Campbell Avenue, New Haven, CT 06516, USA
Arch Gen Psychiatry 62:877-88. 2005..Adaptations in gamma-aminobutyric acid type A (GABA(A))-benzodiazepine receptors contribute to the neurobiology of human alcohol dependence and withdrawal... - Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokersJulie K Staley
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06511, USA
J Neurosci 26:8707-14. 2006..Greater beta2*-nAChR availability during early abstinence may impact the ability of smokers to maintain abstinence... - Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitorsAkira Kugaya
Department of Psychiatry, Yale University, New Haven, Connecticut, USA
Biol Psychiatry 56:497-502. 2004..This study used brain imaging to examine the relationship between pretreatment brain SERT availability and transporter occupancy by SSRIs with treatment response in two independent depressed populations... - Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal womenAkira Kugaya
Department of Psychiatry, Yale University, New Haven, Conn 06516, USA
Am J Psychiatry 160:1522-4. 2003..This study investigated the effect of estrogen on brain serotonin 2A (5-HT(2A)) receptors in postmenopausal women and whether there was any correlation of receptor changes with cognition and mood... - A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United StatesJaakko Lappalainen
Yale University School of Medicine, Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Ave, Psychiatry 116A2, West Haven, CT 06516, USA
Arch Gen Psychiatry 59:825-31. 2002..We tested whether the Pro7 allele is associated with alcohol dependence in European Americans (EA)... - BDNF variants, premorbid educational attainment, and disease characteristics in Alzheimer's disease: an exploratory studyKristina F Zdanys
Alzheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
J Alzheimers Dis 17:887-98. 2009..The effect of the Val66Met polymorphism on premorbid educational attainment is intriguing and should be verified in a larger sample... - Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animalsBrian P Ramos
Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Learn Mem 13:770-6. 2006..These results are consistent with alpha2A-adrenoceptor stimulation enhancing PFC working-memory function via inhibition of cAMP-mediated signaling... - Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependenceHuiping Zhang
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA
Am J Med Genet B Neuropsychiatr Genet 141:387-93. 2006..The negative results for AFDs, PTSD, and schizophrenia could be due to the low statistical power. Further study with larger samples is warranted... - Volumetry of amygdala and hippocampus and memory performance in Alzheimer's diseaseMichael Basso
Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, One Church Street, New Haven, CT 06510, USA
Psychiatry Res 146:251-61. 2006..While a substantial literature continues to justify the focus on the hippocampus in MRI studies of AD, these results suggest that the amygdala should receive similar attention, including in studies of the prodromal stages of AD... - Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's diseaseKristina F Zdanys
Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, CT 06510, USA
Neuropsychopharmacology 32:171-9. 2007..In conclusion, AD patients who carry the ApoE epsilon4 allele are at greater risk than noncarriers for developing psychotic symptoms, particularly as the severity of their dementia progresses... - Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's diseaseMichael Basso
Alzheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, One Church Street, Suite 600, New Haven, CT 06510, USA
Neurobiol Aging 27:1416-24. 2006..These results suggest accelerated atrophy of the amygdala in AD in association with ApoE epsilon4 and provide further evidence for regionally specific effects of this allele... - Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stressAvis Brennan Hains
Department of Neurobiology, Yale University School of Medicine, 333 Cedar Street SHM C 303, New Haven, CT 06510, USA
Proc Natl Acad Sci U S A 106:17957-62. 2009.... - Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysisFrederick A Schmitt
Department of Neurology, University of Kentucky Medical Center, Sanders Brown Center on Aging, Lexington, KY 40536, USA
Alzheimer Dis Assoc Disord 20:255-62. 2006.... - Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPETMasahiro Fujita
Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD 20892 0135, USA
Eur J Nucl Med Mol Imaging 30:1620-9. 2003..These results demonstrate the feasibility of quantifying high-affinity type nAChRs using [123I]5-I-A-85380 in humans and support the use of VT' measured by bolus studies... - Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman
Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
Arch Neurol 61:59-66. 2004..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD... - Vitamin E and donepezil for the treatment of mild cognitive impairmentRonald C Petersen
Mayo Clinic College of Medicine, Rochester, Minn, USA
N Engl J Med 352:2379-88. 2005.... - Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trialsJason Karlawish
Department of Medicine, Alzheimer s Disease Center, Leonard Davis Institute for Health Economics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, School of Medicine, PA, USA
Am J Geriatr Psychiatry 16:568-74. 2008..Among Alzheimer disease (AD) patients enrolled in a clinical trial, the authors assessed the ability of a standardized capacity assessment procedure to identify persons who are capable of giving their own informed consent... - The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollmentJason Karlawish
Department of Medicine, Alzheimer s Disease Center, Leonard Davis Institute for Health Economics, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
Am J Geriatr Psychiatry 16:240-7. 2008..To examine the views of Alzheimer disease (AD) patients and their study partners on the ethics of proxy consent for clinical research... - NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)Illana Gozes
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
CNS Drug Rev 11:353-68. 2005..NAP is poised for further clinical development targeting several indications, including Alzheimer's disease... - Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairmentAdam Fleisher
Department of Neurosciences, University of California San Diego, La Jolla, Calif, USA
Arch Neurol 62:953-7. 2005..The presence of the apolipoprotein E epsilon4 (APOE*E4) allele has been associated with greater hippocampal atrophy in women than in men with Alzheimer disease. This relationship has not been demonstrated in MCI... - High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trialPaul S Aisen
Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
JAMA 300:1774-83. 2008..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
Research Grants
- Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly SubjectsChristopher H van Dyck; Fiscal Year: 2010..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..